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Abstract 1 
Background 2 
Asthma pathophysiology and treatment responsiveness are predicted by inflammatory 3 
phenotype. However, the relationship between airway microbiology and asthma phenotype is 4 
poorly understood. We aimed to characterise airway microbiota in patients with symptomatic 5 
stable asthma, and relate composition to airway inflammatory phenotype and other 6 
phenotypic characteristics.  7 
Methods  8 
The microbial composition of induced sputum specimens collected from adult patients 9 
screened for a multicenter randomized controlled trial was determined by 16S rRNA gene 10 
sequencing. Inflammatory phenotypes were defined by sputum neutrophil and eosinophil cell 11 
proportions. Microbiota were defined using alpha and beta diversity measures, and inter-12 
phenotype differences identified using SIMPER, network analysis, and taxon fold change. 13 
Phenotypic predictors of airway microbiology were identified using multivariate linear 14 
regression. 15 
Results 16 
Microbiota composition was determined in 167 participants, classified as eosinophilic (n=84), 17 
neutrophilic (n=14), paucigranulocytic (n=60), or mixed neutrophilic-eosinophilic (n=9) 18 
phenotypes of asthma. Airway microbiology was significantly less diverse (p=0.022) and 19 
more dissimilar (p=0.005) in neutrophilic compared to eosinophilic participants. Sputum 20 
neutrophil proportion, but not eosinophil proportion, correlated significantly with these 21 
diversity measures (alpha-diversity: Spearman’s r=-0.374, p<0.001; beta-diversity: r=0.238, 22 
p=0.002). Inter-phenotype differences were characterised by a greater frequency of 23 
pathogenic taxa at high relative abundance, and reduced Streptococcus, Gemella and 24 
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Porphyromonas relative abundance in neutrophilic asthma. Multivariate regression confirmed 25 
sputum neutrophil proportion was the strongest predictor of microbiota composition.  26 
Conclusions 27 
Neutrophilic asthma is associated with airway microbiology that is significantly different to 28 
that in other inflammatory phenotypes, particularly eosinophilic asthma. Differences in 29 
microbiota composition may influence response to antimicrobial and steroid therapies, and 30 
risk of lung infection.  31 
  32 
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Key Messages  33 
• Lower airway microbiology differs significantly between neutrophilic and 34 
eosinophilic patients with asthma, characterised by both increased frequency of 35 
pathogenic taxa and divergence in the wider airway microbiota. 36 
• Sputum neutrophilia is the strongest predictor of airway microbiota composition, with 37 
age, ICS dose, gender, and atopy also independent predictors. 38 
• The clear relationships between airway microbiota composition, inflammatory 39 
phenotype, and clinical measures suggest microbiota characterisation could be a useful 40 
contributor to the individualisation of asthma treatments. 41 
Capsule summary  42 
Utilizing a large, well-defined severe asthma cohort, we show that sputum neutrophilia, but 43 
not eosinophilia, was a strong predictor for airway microbiota diversity. These results 44 
highlight the divergence in pathophysiology based on asthma inflammatory phenotype. 45 
Abbreviations. 46 
ACQ6: Asthma Control Questionnaire 6 47 
ANOVA: Analysis of variance 48 
FEV1: Forced expiratory volume in 1 second  49 
FVC: Forced vital capacity 50 
ICS: Inhaled corticosteroid 51 
OTU: operational taxonomic unit 52 
PERMANOVA: Permutational multiple ANOVA  53 
SIMPER: Similarity of percentages 54 
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Introduction  59 
Evidence-based patient stratification is required to address the heterogeneity of asthma 60 
severity and treatment responsiveness. Asthma phenotypes, based on characteristics of airway 61 
inflammation, are increasingly recognised as an important prognostic indicator.1 In addition to 62 
an allergen-induced Th2-lymphocyte, IL-5 mediated, eosinophilic inflammatory response, 63 
asthma can also occur in the absence of eosinophilic inflammation (termed non-eosinophilic 64 
asthma).2, 3 Indeed, based on relative numbers of sputum eosinophils and neutrophils, four 65 
inflammatory subtypes: eosinophilic asthma, neutrophilic asthma, mixed granulocytic asthma, 66 
and paucigranulocytic asthma, have been described.2  67 
Unlike the relatively well-defined mechanisms that result in eosinophilic airway 68 
inflammation, those leading to non-eosinophilic asthma, particularly neutrophilic asthma, 69 
remain relatively poorly understood.4 Further, while non-eosinophilic phenotypes occur 70 
across the spectrum of asthma severity,1, 2, 5 they typically respond poorly to corticosteroids.2, 5 71 
Inflammatory phenotypes have also been shown to differ with respect to airway microbiology. 72 
Compared with other patients with asthma, those with neutrophilic asthma are more likely to 73 
have a potentially pathogenic organism identified, by either culture-based6 or culture-74 
independent approaches,5 and have reduced airway bacterial diversity.7 Given that airway 75 
microbiota composition is associated with the degree of airway hyper-responsiveness among 76 
patients with sub-optimally controlled asthma,8 inter-phenotype differences in airway 77 
microbiology are likely to be clinically important. 78 
The relationships between asthma inflammatory phenotypes and airway microbiology are 79 
likely to be complex and bi-directional. Asthma phenotypes represent immunological and 80 
physicochemical differences within the lower airways that are likely to be reflected, through 81 
their selective effect on microbial growth and airway clearance, in divergent lower airway 82 
microbiota.9 Where these differences involve the increased abundance of particular 83 
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respiratory pathogens, or a depletion of commensal populations, they could contribute 84 
substantially to the course of airway disease or risk of adverse treatment events, such as 85 
corticosteroid associated pneumonia.10 On the other hand, the characteristics of airway 86 
microbiology, even in the absence of frank infection, could influence asthma inflammatory 87 
phenotype. Defining the relationships between inflammatory phenotype and lower airway 88 
microbiota would inform our understanding of asthma pathophysiology, and could help to 89 
identify prognostic markers.  90 
Several previous studies have reported differences in airway microbiology in eosinophilic and 91 
non-eosinophilic asthma, and the existence of significant relationships between this 92 
microbiota composition and clinical asthma measures.5, 11-14 However, while providing 93 
important insight, these studies have involved relatively small and heterogeneous patient 94 
cohorts. Our study, based on participants enrolled into the Asthma and Macrolides: the 95 
Azithromycin Efficacy and Safety Study (AMAZES) trial (ACTRN12609000197235), was 96 
over three times the size of any study performed previously and focused on a well-defined 97 
population of patients with severe but stable asthma, the majority of whom were treated with 98 
inhaled corticosteroids.  99 
Through the application of a systematic approach to microbiota characterisation, we aimed to 100 
assess whether asthma inflammatory phenotypes were associated with substantially different 101 
lower airway bacteriology (herein referred to as microbiology), to identify bacterial taxa that 102 
discriminate among inflammatory phenotypes, and to determine the contribution of patient 103 
and clinical characteristics to variation in the composition of the bacterial component of the 104 
microbiome.   105 
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Methods  106 
Study population 107 
For full methodology see Supplementary Methods. Analysis was performed on samples 108 
collected as part of the baseline screening population from AMAZES clinical trial 109 
(ACTRN12609000197235). Participants were recruited from eight centres across Australia 110 
(detailed in Supplementary Methods). Pre-defined inflammatory phenotype categories, based 111 
on sputum cell counts relative to patient age, were assigned as published previously and 112 
detailed in the Supplementary Methods.15, 16 Briefly, neutrophilic phenotype was defined as 113 
≥61% neutrophils (neutrophil% cut-off dependent on age), eosinophilic phenotype as ≥3% 114 
eosinophils, paucigranulocytic as ≤61% neutrophils and ≤3% eosinophils and mixed 115 
granulocytic was defined as ≥61% neutrophils and ≥3% eosinophils.  116 
 117 
DNA extraction and 16S rRNA gene amplicon sequencing and gene copy number 118 
DNA extraction was performed on 100 µl sputum aliquots using a combined physical, 119 
enzymatic, and heat-based cell lysis, followed by phenol-chloroform extraction and DNA 120 
recovery using EZ-10 Spin columns (Bio Basic, Inc., Ontario, Canada). V1-3 hypervariable 121 
region of the bacterial 16S rRNA gene was amplified from sputum DNA using modified 122 
primers 27F and 519R. Amplicons were cleaned, indexed and sequenced according to the 123 
Illumina MiSeq 16S Metagenomic Sequencing Library Preparation protocol. 16S rRNA 124 
sequence data was processed as previously described.17 Spurious operational taxonomic units 125 
(OTUs) were removed systematically using previous reports of common laboratory 126 
sequencing contaminants.18 Bacterial burden was quantified using qPCR for the 16S rRNA 127 
gene.19 Detailed extraction, sequencing and qPCR protocols are provided as Supplementary 128 
Methods. 129 
 130 
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Diversity measurements and statistical analyses 131 
Five alpha diversity (within-sample variance) indices were employed to test a variety of 132 
parameters of within-patient taxon distribution: Faith’s phylogenetic diversity (where a higher 133 
value indicates a more phylogenetically diverse sample), Simpson’s and Pielou’s evenness 134 
indices (where a higher value indicates a more equitable distribution of taxa abundance), taxa 135 
richness (the total number of taxa detected), and Shannon-Weiner diversity (a measure 136 
incorporating both the number and equitability of detected taxa). Beta diversity (inter-sample 137 
variance) was determined by using two approaches: weighted UniFrac similarity (which 138 
accounts for phylogenetic distance) and square-root transformed Bray- urtis similarity (based 139 
on the relative abundance of taxa alone). Alpha and beta diversity measures were calculated 140 
using either QIIME (v. 1.8.0) or Primer (v. 6, PRIMER E Ltd, Plymouth, UK). 141 
Continuous data were tested for non-normality including skewness and kurtosis using the 142 
D’Agostino-Pearson omnibus test. The Kruskal-Wallis one-way ANOVA with Dunn’s post 143 
hoc test was used for multiple comparisons of non-normally distributed data, Mann-Whitney 144 
U test for pairwise comparisons, chi-squared test for categorical data, and Spearman’s test for 145 
correlations (GraphPad PRISM; v.7.01 GraphPad Software Inc., California, USA).  146 
Multivariate linear regression was performed using Faith’s phylogenetic diversity and 147 
UniFrac distance from centroid as two dependent variables reflecting aspects of diversity 148 
(SPSS v.23.0, IBM, Armonk, NY). Covariates were selected a priori and included in the 149 
model based on a significant correlation with either dependent variable. Confidence intervals 150 
were obtained by bootstrapping; resampling 1,000 times. Covariates were tested for 151 
collinearity using variance inflation factors. 152 
 153 
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Taxon dispersion 154 
Variation in microbiota composition between groups was assessed using SIMilarity of 155 
PERcentages (SIMPER) analysis in PRIMER, and SparCC from which correlations (r≥0.25 156 
or r≤-0.25) and p values (p≤0.01) were visualized by network analysis using Cytoscape 157 
(v.3.4.0). Pathogen overgrowth adjustment is described in Supplementary Methods.  158 
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Results 159 
Clinical characteristics 160 
Induced sputum samples were obtained from 187 participants. Of these, thirteen were 161 
excluded due to poor sample quality. Of the 174 that underwent 16S rRNA gene amplicon 162 
sequencing, a further seven were excluded due to an insufficient sequence read depth 163 
(Supplementary Table 1). The remaining 167 subjects were classified as one of four 164 
inflammatory phenotypes: neutrophilic (n=14), eosinophilic (n=84), paucigranulocytic 165 
(n=60), or mixed granulocytic (n=9) based on previously described sputum inflammatory cell 166 
count percentages.15, 16 There was no significant difference in age, gender distribution, atopy, 167 
smoking history, ICS dose, GINA treatment step, or mean ACQ6 score between these 168 
phenotypic groups, as assessed using multiple comparison tests (Table 1). There were, 169 
however, significant differences in lung function, as assessed by both FEV1 % predicted 170 
(p=0.035) and FEV1/FVC% (p=0.013). 171 
Following quality filtering and chimera removal, 16S rRNA gene amplicon sequencing 172 
resulted in a median read depth of 12,792 (q1, q3: 8060, 16595). Sequence data was sub-173 
sampled to a uniform depth of 1,732 reads based on rarefaction curve asymptotes and Good’s 174 
coverage values. No significant differences in total bacterial burden were found between 175 
inflammatory phenotypes (p=0.51, Kruskal-Wallis test, Supplementary Figure 1). 176 
 177 
Alpha diversity 178 
Participants with neutrophilic asthma had significantly lower Faith’s phylogenetic score 179 
(p=0.022) than participants with eosinophilic asthma, which resembled that of 180 
paucigranulocytic asthma (Figure 1A). Faith’s phylogenetic diversity significantly correlated 181 
with the sputum neutrophil % (r=-0.374, p<0.0001; Figure 1B) but not with sputum 182 
eosinophil % (r=0.146, p=0.060; Figure 1C). Analysis with a range of alternative alpha 183 
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diversity indices (taxa richness, Shannon-Wiener index, Simpson’s index, and Pielou’s 184 
evenness; Supplementary Figures 2 and 3), resulted in consistent findings in relation to 185 
phenotype, sputum neutrophil % and sputum eosinophil %. Together, these results 186 
demonstrate a significant relationship between airway microbiota composition and sputum 187 
neutrophilia, but not sputum eosinophilia. 188 
 189 
Beta diversity 190 
Principal Coordinate Analysis (PCoA) of weighted UniFrac similarity distance showed that 191 
neutrophilic samples were distinguished from other phenotypes along the first and second 192 
principal coordinates, while the other phenotypes broadly clustered together (Figure 2A). 193 
Consistent with these observations, a PERMANOVA test showed that phenotype grouping 194 
contributed significantly to the differences in microbial composition of the samples 195 
(p=0.0004, pseudo-F=3.997, Supplementary Table 2). Pairwise PERMANOVA comparing the 196 
phenotype groups indicated that variance was attributed to neutrophilic vs eosinophilic 197 
(p=0.0001, T=3.30) and neutrophilic vs paucigranulocytic (p=0.0015, T=2.52) groups 198 
(Supplementary Table 3).  199 
Assessment of microbiota dispersion based on distance from centroid was consistent with 200 
PERMANOVA analysis, with the samples from neutrophilic phenotype participants having 201 
significantly higher distances from the centroid than samples from eosinophilic and 202 
paucigranulocytic participants (Figure 2B). In keeping with alpha diversity analyses, variance 203 
in distance from centroid was associated with sputum neutrophil %, rather than sputum 204 
eosinophil % (Supplementary Figure 4). Beta-diversity analyses using a second distance 205 
measure, Bray-Curtis, gave consistent findings (Supplementary Figure 5). 206 
 207 
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Taxon distribution and network analysis 208 
SIMPER analysis was used to rank taxa according to their contribution to intergroup variance 209 
in microbiota composition. Thirteen taxa were identified which cumulatively accounted for 210 
approximately 50% of total variance between neutrophilic and eosinophilic samples 211 
(Supplementary Table 4). Hierarchical cluster analysis based on relative taxon abundance 212 
revealed that Moraxella and Haemophilus clustered separately from the other eleven taxa 213 
(Figure 3). In the patients with neutrophilic asthma, Moraxella and Haemophilus exceeded 214 
40% relative abundance in 6/14 (42.9%) samples compared to only 1/84 (1.19%) patients 215 
with eosinophilic asthma, 7/60 (11.7%) with paucigranulocytic and 1/9 (11.1%) with mixed 216 
(χ2=25.5, p<0.0001, Figure 3). Relationships between bacterial taxon relative abundance were 217 
further visualised by network analysis (Figure 4, Supplementary Figure 6), revealing a 218 
bacterial community of taxa whose abundance is positively correlated in almost all cases. 219 
Most of these taxa were more prevalent in eosinophilic samples than in neutrophilic samples. 220 
Haemophilus, which had a mean abundance that was higher in neutrophilic samples, was the 221 
single exception, negatively correlating with other members of the sputum bacterial 222 
community.  223 
Of the 13 discriminant taxa identified by SIMPER, Streptococcus II (see Supplementary 224 
Methods for classification), Gemella, Rothia and Porphyromonas were significantly less 225 
abundant in neutrophilic than in eosinophilic and paucigranulocytic phenotypes (Figure 5A). 226 
Sputum neutrophil % positively correlated with the relative abundance of Moraxella and 227 
negatively correlated with the relative abundance of Streptococcus I, Gemella and 228 
Porphyromonas (Figure 5B). In contrast, Haemophilus negatively correlated with eosinophil 229 
%, and Streptococcus I, Neisseria and Gemella positively correlated with eosinophil % 230 
(Supplementary Figure 7). Prevotella, Actinomyces, Leptotrichia, and Veillonella, while 231 
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identified by SIMPER and represented highly connected nodes in the network analysis, did 232 
not differ between airway inflammatory phenotypes, nor correlate with sputum cell counts. 233 
 234 
Non-dominant microbiome 235 
We sought to establish whether differences in microbiota composition between inflammatory 236 
phenotypes were explained solely by overgrowth of opportunistic taxa (e.g. Haemophilus and 237 
Moraxella) or, alternatively, whether differences existed even in the absence of pathogen 238 
predominance. Two separate approaches were used to investigate this; re-scaling of relative 239 
abundance data, following the exclusion of pathogen predominance, and assessment of ranked 240 
taxon fold change between neutrophilic and eosinophilic groups based on non-subsampled 241 
taxa counts. Re-scaled relative abundance data remained significantly different between 242 
inflammatory phenotypes (p=0.0004, pseudo-F=2.38, Supplementary Table 5). Pairwise tests 243 
revealed significant differences between neutrophilic and eosinophilic phenotype participants 244 
(p=0.0001, T=2.31) and between neutrophilic and paucigranulocytic participants (p=0.0002, 245 
T=2.26, Supplementary Table 5). Assessment of taxa count ranked fold change supported 246 
these findings, with significant taxa count differences between participants with neutrophilic 247 
and eosinophilic phenotypes (Supplementary Figure 8). 248 
 249 
Clinical and inflammatory associations with microbiota composition  250 
In univariate analysis, Faith’s phylogenetic diversity significantly, inversely correlated with 251 
sputum neutrophil %, age, and ICS dose, and significantly, positively with FEV1 % (Table 2). 252 
Conversely, weighted UniFrac distance from centroid significantly correlated, positively with 253 
sputum neutrophil %, and was significantly different based on gender and atopy but not with 254 
age, ICS dose, FEV1 % or previous smoking status (Table 2). In multivariate analysis sputum 255 
neutrophil % was the only variable that independently predicted both Faith’s phylogenetic 256 
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diversity and weighted UniFrac distance from centroid (p=0.002, 95% CI=-0.07, -0.02 and 257 
p<0.001, 95% CI=0.07, 0.22, respectively; Table 3). Age and ICS dose both independently 258 
predicted Faith’s diversity (p=0.030, 95% CI=-0.07, -0.004 and p=0.042, 95% CI=-0.001, -259 
0.001, respectively) while atopy and gender independently predicted distance from centroid 260 
(p=0.018, 95% CI=1.3, 8.4 and p=0.039, 95% CI=-7.5, -0.30, respectively).  261 
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Discussion 262 
To our knowledge, this is the largest study to date to assess predictors of the airway 263 
microbiota composition in asthma. Our primary comparisons were between asthma 264 
inflammatory phenotypes, where we observed significant differences in the composition of 265 
airway microbiota. These differences were largely between neutrophilic and eosinophilic 266 
participants, and reflected a reduced diversity and evenness of detectable bacterial taxa in the 267 
neutrophilic participants. Reduced microbiota diversity has been reported following acute and 268 
chronic airway infections in asthma,5, 7 and in other respiratory disorders,20-22 as well as with 269 
the effects of exposure to antibiotics.23, 24 Importantly, none of the study participants reported 270 
clinical features of respiratory infection or had antibiotic therapy during the preceding month.  271 
We further assessed alpha diversity metrics relative to continuous neutrophil and eosinophil 272 
count data as an alternative to categorical inflammatory phenotypes. Significant correlations 273 
were observed between sputum neutrophil % and each assessed alpha diversity metric, with 274 
no significant interactions between any diversity metric and sputum eosinophil %, strongly 275 
suggesting that decreased microbiota richness, evenness, and diversity are associated with 276 
airway neutrophilia. Analysis of sputum microbiota beta diversity (inter-sample similarity) 277 
also demonstrated substantial differences between people with neutrophilic airway 278 
inflammation and those with other inflammatory phenotypes, consistent with the stochastic 279 
overgrowth of complex commensal communities by individual opportunistic pathogens.25 280 
We identified bacterial taxa that contributed to observed differences in microbiota 281 
composition between inflammatory phenotypes, namely high abundance of Haemophilus and 282 
Moraxella in neutrophilic participants, supporting previous findings (5). This could be 283 
interpreted as simply an increased relative abundance of airway pathogens in neutrophilic 284 
patients, reflecting neutrophilic influx into the airways during sub-clinical lower airway 285 
infection, with a reciprocal decrease in the relative abundance of commensal taxa. However, a 286 
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group of common airway taxa correlated negatively with sputum neutrophil % (Gemella, 287 
Porphyromonas, and Streptococcus) and, importantly, even after overgrowth effects of 288 
Haemophilus and Moraxella were controlled for, significant differences in the microbiota 289 
composition between neutrophilic and eosinophilic participants were still observed. This 290 
finding suggests that two separate phenomena contribute to microbial differences between 291 
inflammatory phenotypes; the impact of pathogen overgrowth, and the selective pressure of 292 
airway inflammatory characteristics in the absence of infection. The latter could result in 293 
more broad-scale divergence in composition between neutrophilic and eosinophilic 294 
subgroups, in turn, contributing to an increased risk of lower airway infection in neutrophilic 295 
patients through an increased presence of opportunistic pathogens.  296 
This finding has clear implications for the clinical management of asthma, where low-dose 297 
macrolide and ICS therapies have been shown to influence overgrowth by opportunistic 298 
respiratory pathogens and innate immune function, respectively.6, 14, 26 Further, the relative 299 
lack of efficacy of ICS in patients with non-eosinophilic asthma2 may lead to use of higher 300 
doses compared to eosinophilic patients. The combination of underlying differences in airway 301 
microbiota (associated with differences in inflammatory phenotype) and inefficacious 302 
therapies being used at higher doses might contribute to reduced bacterial diversity,14 the high 303 
concentrations of Proteobacteria seen in the airways of neutrophilic patients,7 a greater 304 
propensity for lung infection, and a further enhancement of the neutrophilic phenotype.6 305 
While strong associations between neutrophilic phenotype and sputum microbiota 306 
composition were found, associations between eosinophil counts and microbiota composition 307 
were minimal. This contrasts with previous studies reporting increased Tropheryma associated 308 
with eosinophilia,7 and associations between bronchial biopsy eosinophil count and bacterial 309 
composition,11 and reduced bacterial burden associated with type 2-high airway 310 
inflammation.27 311 
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An important strength of our study was its involvement of a large group of well-defined 312 
participants with poorly controlled asthma, who were taking regular inhaled therapy. The 313 
application of detailed induced sputum microbiota characterisation from these participants 314 
then allowed us to assess the extent to which clinical and inflammatory characteristics 315 
independently associated with variations in airway microbiology using multivariate linear 316 
regression analysis. Multivariate regression identified sputum neutrophil % as the strongest 317 
predictor of microbiota variance. However age, ICS dose, gender and atopy were also 318 
significant, independent predictors. Conversely, lung function (as measured by FEV1 %) and 319 
smoking status were not. Of particular interest was the finding that increasing age predicted 320 
reduced microbiota alpha diversity, as age has been previously associated with microbiome 321 
composition in other chronic respiratory diseases. The airway microbiome of cystic fibrosis 322 
patients is strongly affected by age,28 which is presumed to relate to the selective effects of 323 
increased antibiotic exposure over time and the changing characteristics of the airway 324 
environment.9 It is interesting to speculate that the relationship between neutrophilia and 325 
microbiota composition may reflect the effect of age on neutrophilia,15 suggesting that a 326 
tendency towards a neutrophilic phenotype and/or a susceptibility to opportunistic airway 327 
infections increases with age in patients with severe asthma.  328 
It is important to recognise a number of limitations of our study. Airway microbiology was 329 
assessed based on induced sputum, which, while shown to provide reproducible inflammatory 330 
cell levels in patients with moderate to severe asthma,29, 30 only provides an approximation of 331 
lower airway microbiology (in common with other lower airway sampling strategies).31 It is 332 
also important to note that induced sputum levels of neutrophils and eosinophils may change 333 
frequently,32, 33 and that the relationships between airway microbiology and inflammatory 334 
phenotype reported are cross-sectional. Detailed longitudinal analysis is now required to 335 
determine how these relationships change with time. 16S rRNA gene amplicon sequence data 336 
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was subsampled to a level that allowed the inclusion of the greatest number of subjects, while 337 
maintaining sufficient read depth to accurately describe microbiota composition. Additional 338 
analysis, using a greater read depth, might however identify rare taxa that contribute to 339 
disease characteristics. While multivariate regression identified sputum neutrophilia as an 340 
independent predictor of microbiota composition, the effects of variation in ICS dose between 341 
phenotypes (although non-significant) should be noted. Finally, though none of the study 342 
participants received antibiotics in the month prior to recruitment, data on less recent 343 
exposure were not available and could have a lasting impact on the lower airway microbiome 344 
composition.23 345 
The clear relationship between airway inflammatory phenotype and microbiota highlight the 346 
need for studies examining whether asthma treatments should be individualised based on both 347 
inflammatory phenotype stratification and lower airway microbiology. There is now a clear 348 
need to investigate the extent to which variations in the airway microbiota predict the risk of 349 
future asthma exacerbations, and to determine whether airway microbiota characterisation 350 
could be used as a basis for asthma treatment selection.  351 
 352 
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Table 1: Clinical and inflammatory cell parameters of participants 
 Neutrophilic Eosinophilic Paucigranulocytic Mixed Granulocytic p 
N 14 84 60 9  
Age, mean (SD) 59.8 (13.9) 57.2 (15.2) 55.8 (13.8) 56.8 (17.8) 0.817 
Male, n (%) 9 (64.3) 30 (35.7) 23 (38.3) 6 (66.7) 0.084 
Atopic, n (%) 11 (78.6) 62 (76.5), n=81 52 (86.7) 6 (66.7) 0.305 
Previous smoker, n (%) 6 (42.9) 32 (38.1) 17 (28.3) 4 (44.4) 0.491 
Smoking pack years, median 
(q1,q3) 
22.0 (18.6,27.5) 5.3 (1.2, 15.9) 5.0 (1.3, 30.0) 4.4 (0.9, 63.6) 0.379 
Duration of asthma, years 
median (q1,q3) 
33.8 (3.5, 48.3) 36.3 (19.7, 49.2) 33.7 (14.2, 54.4) 53.6 (32.6, 60.4) 0.205 
FEV1 % predicted, mean (SD) 70.3 (18.2) 70.0 (17.9) 78.7 (19.2)* 68.4 (17.3) 0.035 
FVC % predicted, mean (SD) 81.4 (11.6) 83.6 (16.4) 85.1 (15.0) 82.9 (11.7) 0.854 
FEV1/FVC %, mean (SD) 65.8 (14.5) 64.9 (12.2) 71.3 (12.2)* 63.9 (12.7) 0.013 
ACQ6, mean (SD) 2.1 (1.2) 1.9 (0.9) 1.6 (0.8) 1.5 (0.6) 0.210 
GINA Treatment step 
1 
2 
3 
4 
5 
 
1 (7.1) 
0 (0) 
0 (0) 
11 (78.6) 
2 (14.3) 
 
2 (2.5) 
0 (0) 
10 (12.4) 
67 (82.7) 
2 (2.5) 
 
0 (0) 
0 (0) 
12 (20.3) 
47 (80.0) 
0 (0) 
 
0 (0) 
0 (0) 
2 (22.2) 
7 (77.8) 
0 (0) 
0.058 
ICS dose, µg, median (q1,q3) 2000 (1280,2000), 
n=13 
1000 (800,2000), 
n=82 
1000 (800,2000), 
n=59 
1600 (1000, 2000) 0.254 
Total cell count, x 106/mL 
(q1,q3) 
9.8 (7.6, 12.7)* † 3.6 (1.9, 7.6) 3.74 (2.0, 7.6) 8.64 (5.22, 11.34) <0.001 
Viability, % 89.2 (73.5, 93.0)* † 69.8 (52.2, 80.7) 68.9 (55.7, 79.5) 90.0 (84.4, 93.7)* † <0.001 
Neutrophils, % 75.0 (68.80, 84.00)* † 27.13 (14.38, 41.00) 34.13 (12.63, 49.25) 77.00 (71.25, 77.50)* † <0.001 
Eosinophils, % 0.63 (0.50, 1.00)* 6.88 (3.63, 18.13) 0.25 (0.00, 1.00)* 6.75 (3.25, 12.25)# † <0.001 
Macrophages, % 20.75 (14.50, 30.25)* † 52.75 (38.25, 71.00) 53.34 (43.50, 75.63) 16.00 (15.50, 20.25) *† <0.001 
Lymphocytes, % 0.63 (0.25, 1.00) 1.13 (0.25, 2.25) 0.88 (0.25, 2.63) 0.25 (0.00, 0.38)* † 0.018 
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Columnar epithelial cells, % 0.25 (0.00, 1.25)* † 2.17 (0.75, 6.00) 4.13 (1.21, 8.50) 0.50 (0.25, 1.50) † <0.001 
Squamous cells, % 1.11 (0.50, 3.85)* † 5.99 (2.32,16.23) 6.18 (2.92, 11.31) 3.38 (0.25, 8.05) 0.002 
 
ACQ6: asthma control questionnaire 6 question format, FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, ICS: inhaled 
corticosteroids, SD: standard deviation, q1, q3: quartile 1, quartile 3. P values in last column describe variance across four phenotypes. *p<0.05 
vs eosinophilic asthma, †p<0.05 vs. paucigranulocytic, #p<0.05 vs. neutrophilic asthma.
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Table 2: Comparison of patient characteristics with alpha diversity (Faith’s phylogenetic 
diversity) and beta diversity (weighted UniFrac distance from centroid). Assessed using 
Spearman or Mann-Whitney test. 
    
Neutrophil 
% Age 
ICS 
Dose* 
FEV1 % 
predicted Atopy†# Gender† 
Ever 
smoked† 
Faith's 
diversity 
r -0.374 -0.309 -0.242 0.193    
p <0.001 <0.001 0.002 0.013 0.32 0.97 0.53 
UniFrac 
Distance 
r 0.24 0.015 0.096 0.034    
p 0.002 0.84 0.22 0.66 0.019 0.003 0.70 
Spearman correlation coefficient (r) and probability values are as indicated. 
*n=163 
#n=164 
†Assessed using Mann-Whitney test 
 
 
Table 3: Multivariate linear regression on alpha diversity (Faith’s phylogenetic diversity) and 
beta diversity (weighted UniFrac distance from centroid). Performed on 160 participants. 
 
B 95% CI p 
Faith's 
phylogenetic 
diversity 
Neutrophil % 
-0.046 -0.07, -0.02 0.002 
Age 
-0.036 -0.07, -0.004 0.030 
Gender 0.35 -0.59, 1.4 0.49 
Atopy 
-0.77 -1.7, 0.12 0.10 
FEV1 % predicted 0.016 -0.01, 0.04 0.23 
ICS dose 
-0.001 -0.001, -0.001 0.042 
UniFrac 
distance 
from 
centroid 
Neutrophil % 0.14 0.07, 0.22 <0.001 
Age 0.056 -0.05, 0.16 0.30 
Gender -3.9 -7.5, -0.30 0.039 
Atopy 4.8 1.3, 8.4 0.018 
FEV1 % predicted 0.049 -0.04, 0.14 0.27 
ICS dose <0.001 -0.001, 0.001 0.56 
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Figure Legends 
Figure 1: Faith’s phylogenetic diversity is significantly associated with sputum neutrophilia 
but not eosinophilia. A) Patients grouped by asthma phenotype. B) Neutrophil % where 
dotted line at 61% neutrophils indicates phenotype cut-off point. C) Eosinophil % where 
dotted line at 3% eosinophils indicates phenotype cut-off point. Colours represent asthma 
phenotype, where blue= >61% neutrophils, green= >3% eosinophils, yellow= <61% 
neutrophils and <3% eosinophils (paucigranulocytic), and purple= both >61% neutrophils 
and >3% eosinophils (mixed). Statistical significance was assessed by A) Kruskal-Wallis one-
way ANOVA with Dunn’s post hoc test or B) and C) Spearman’s rank correlation. 
 
Figure 2: Microbiota dispersion grouped by asthma phenotype. A) Principal Coordinate 
Analysis (PCoA). The first two principal coordinates are plotted on the x- and y-axes, 
respectively (representing 59.9% of the total variation). B) Distance from centroid. Statistical 
significance was assessed by Kruskal-Wallis one-way ANOVA with Dunn’s post hoc test. 
 
Figure 3: Relative abundance of discriminant taxa among asthma phenotypes. The thirteen 
taxa that collectively contribute to approximately 50% of variance among phenotypes, as 
determined by SIMPER analysis. The clustering shows the similarity relationship of genera 
based on Bray-Curtis similarity distance and single linkage hierarchical clustering method. * 
Actinomyces sp. uncultured bacteria, # Actinomyces sp. oral clone DR002. 
 
Figure 4: Bacterial network analysis of asthma cohort. Each edge represents a significant 
correlation coloured by either positive (blue) or negative (red). Edge width and transparency 
are proportional to the absolute value of the correlation coefficient. Node size is proportional 
to mean relative abundance. Node hue is proportional to the difference in taxon relative 
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abundance between the neutrophilic phenotype group and the eosinophilic phenotype group. 
Correlations performed by SparCC with a correlation cut-off of R>0.25 or <-0.25. * 
Actinomyces sp. uncultured bacteria, # Actinomyces sp. oral clone DR002. 
 
Figure 5: Taxa distribution differs by sputum neutrophilia. A) Taxa which significantly differ 
by patient inflammatory phenotype. B) Significant correlations between taxa and neutrophil 
%. Colours represent asthma phenotype, based on neutrophilia or eosinophilia where blue= 
>61% neutrophils, green= >3% eosinophils, yellow= <61% neutrophils and <3% eosinophils 
(paucigranulocytic), and purple= both >61% neutrophils and >3% eosinophils (mixed). 
Dotted line at 61% neutrophils indicates phenotype cut-off point. Statistical significance was 
assessed by A) Kruskal-Wallis one-way ANOVA with Dunn’s post hoc test and B) 
Spearman’s rank correlation.  
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Inflammatory phenotypes in severe asthma are associated with distinct airway 
microbiology  
 
Steven L. Taylor*, Lex E.X. Leong*, Jocelyn M. Choo, Steve Wesselingh, Ian A. Yang, John 
W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Christine Jenkins, Matthew J. 
Peters, Melissa Baraket, Guy B. Marks, Peter G. Gibson, Jodie L. Simpson†, Geraint B. 
Rogers†
 
 
Supplementary Methods 
Exclusion criteria 
Asthma diagnosis was established using American Thoracic Society guidelines based on 
current episodic respiratory symptoms, clinical diagnosis and evidence of variable airflow 
obstruction.1 Participants with asthma were included if stable but symptomatic, despite being 
prescribed maintenance inhaled corticosteroid (ICS) and long acting bronchodilator treatment 
with an Asthma Control Questionnaire 6 (ACQ6) score >0.75.2 
Participants with an FEV1 <40% predicted, current smokers, ex-smokers who had ceased 
smoking in the previous year and those with a recent (past four weeks) exacerbation or 
respiratory infection were excluded. Those with significant smoking related air-space disease 
(ex-smokers >10 pack year history and DLCO/VA <70% predicted OR smoking history >10 
pack years and exhaled carbon monoxide >10ppm) were also excluded. This study was 
conducted in accordance with the amended Declaration of Helsinki. Local institutional review 
boards approved the protocol and written informed consent was obtained from all 
participants. 
 
Institutional centres 
Sputum samples were collected from eight Australian centres: 
Hunter Medical Research Institute, Newcastle NSW Australia 
The Prince Charles Hospital, Chermside, QLD, Australia 
Princess Alexandra Hospital, Woolloongabba QLD, Australia 
Royal Adelaide Hospital, Adelaide SA, Australia 
Sir Charles Gairdner Hospital, Nedlands WA, Australia 
Woolcock Institute of Medical Research, Glebe NSW, Australia 
Concord Repatriation General Hospital, Concord NSW, Australia 
Liverpool Hospital, Liverpool NSW, Australia 
 
Sample collection 
All study participants attended a single visit that included the assessment of lung function 
asthma symptoms, asthma specific quality of life,3 medication use and smoking status. 
Sputum induction with hypertonic saline (4.5%) was performed as described previously.4 
Sputum aliquots were stored at -80°C for DNA extraction, or dispersed using dithiothreitol for 
sputum cell count assessment and inflammatory subtype determination.5 
 
Patient inflammatory phenotyping 
Patient sputum was dispersed using dithiothreitol and inflammatory cells were counted as a 
percentage of total sputum cells. Inflammatory subtype was determined as described below. 
Neutrophilic cut-off values were age-dependent as described previously.6, 7  
 
Neutrophilic phenotype 
Neutrophil % (< 20 years old) ≥75.57% 
Neutrophil % (20-40 years old) ≥61.61% 
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Neutrophil % (40-60 years old) ≥63.25% 
Neutrophil % (>60 years old)  ≥67.25% 
Eosinophilic phenotype 
Eosinophil %    ≥3% 
Paucigranulocytic phenotype 
Eosinophil %    ≤3% 
Neutrophil % (< 20 years old) ≤75.57% 
Neutrophil % (20-40 years old) ≤61.61% 
Neutrophil % (40-60 years old) ≤63.25% 
Neutrophil % (>60 years old)  ≤67.25% 
Mixed granulocytic phenotype 
Eosinophil %    ≥3% 
Neutrophil % (< 20 years old) ≥75.57% 
Neutrophil % (20-40 years old) ≥61.61% 
Neutrophil % (40-60 years old) ≥63.25% 
Neutrophil % (>60 years old)  ≥67.25% 
 
DNA extraction  
DNA extraction was performed on sputum sample aliquots of approximately 100 µl. 
Following the addition of 300 µl of phosphate buffered saline, samples were vortexed for 10 
seconds and placed on ice for 2 min. Bacterial cells were then pelleted by centrifugation at 
13,000 x g for 10 min. Following removal of supernatant, 300 µl of Tris-EDTA solution (10 
mM Tris-HCl, 1 mM EDTA; pH 8.0; Ambion, ThermoFisher Scientific, Victoria, Australia), 
200 µg of silica: zirconium beads (1:1 of 0.1 µm and 1.0 µm; Biospec Products, Inc., OK, 
USA), and a single chrome bead (3.2 mm, Biospec Products, Inc., OK, USA) were added to 
the tube containing the cell pellet. Samples underwent bead-beating at 6.5 m/s for 60 sec in a 
FastPrep®-24 Instrument (MP Biomedicals, CA, USA). Homogenised sample was heated to 
90 °C for 5 min, before being cooled on ice for 5 min. Lysozyme (ROCHE, ThermoFisher 
Scientific, Victoria, Australia) and lysostaphin (Sigma-Aldrich, MO, USA) were then added 
to a final concentration of 2 mg/mL and 0.1 mg/mL, respectively, and samples incubated at 37 
°C for 1 hr. Proteinase K (Fermentas, ThermoFisher Scientific, Victoria, Australia) and 
sodium dodecyl sulphate (Sigma-Aldrich, MO, USA) were then added to a final concentration 
of 1.2 mg/mL and 1.5 %, w/v, respectively. Following incubation at 30 min at 56 °C, 40 µl of 
5M sodium chloride and 450 µl of phenol:chloroform:isoamyl alcohol (25:24:1; saline 
buffered at pH8.0; Sigma-Aldrich, MO, USA) were added and samples vortexed for 30 sec. 
The aqueous-organic layers were separated by centrifugation at 13,000 x g for 10 min and 400 
µl of the aqueous layer was transferred to a new microfuge tube. DNA was recovered using 
an EZ-10 Spin column in accordance with manufacturer’s instructions (Bio Basic, Inc., 
Ontario, Canada), following precipitation by the addition of 10 M ammonium acetate and 
99% ethanol (Sigma Aldrich, MO, USA) in a 1:10 and 1:1 ratio with sample volume, 
respectively. DNA was eluted in 50 µl UltraPure DNase/RNase-free distilled water (Gibco, 
ThermoFisher Scientific, Victoria, Australia) and stored at -80 °C prior to analysis.   
 
16S rRNA gene amplicon sequencing 
The V1-3 hypervariable region of the bacterial 16S rRNA gene was amplified from sputum 
DNA using modified primers 27F (5'-
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGRGTTTGATCMTGGCTCAG-3') 
and 519R (5'-
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTNTTACNGCGGCKGCTG-3'), 
with Illumina adapter overhang sequences as indicated by underline. Amplicons were 
generated, cleaned, indexed and sequenced according to the Illumina MiSeq 16S 
Metagenomic Sequencing Library Preparation protocol 
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(http://support.illumina.com/downloads/16s_metagenomic_sequencing_library_preparation.ht
ml) with certain modifications. Briefly, an initial PCR reaction contained at least 12.5 ng of 
DNA, 5 µL of forward primer (1 µM), 5 µL of reverse primer (1 µM) and 12.5 µL of 2× 
KAPA HiFi Hotstart ReadyMix (KAPA Biosystems, Wilmington, MA, USA) in a total 
volume of 25 µL. The PCR reaction was performed on a Veriti 96-well Thermal Cycler (Life 
Technologies) using the following program: 95 °C for 3 min, followed by 25 cycles of 95 °C 
for 30 sec, 55 °C for 30 sec and 72 °C for 30 sec and a final extension step at 72 °C for 5 min. 
Samples were multiplexed using a dual-index approach with the Nextera XT Index kit 
(Illumina Inc., San Diego, CA, USA) according to the manufacturer’s instructions. The final 
library was paired-end sequenced at 2 × 300 bp using a MiSeq Reagent Kit v3 on the Illumina 
MiSeq platform. Sequencing was performed at the David R Gunn Genomics Facility, South 
Australian Health and Medical Research Institute. 
 
16S rRNA gene qPCR 
Approximate 16S rRNA gene copy number was assessed by quantitative PCR (qPCR) using 
the 16S rRNA universal primers B331F (5'-TCCTACGGGAGGCAGCAGT-3') and B797R 
(5'-GGACTACCAGGGTATCTAATCCTGTT-3') using Platinum SYBR Green 
(ThermoFisher scientific, Vic, Australia) as previously described.8 Reactions were performed 
in duplicate and averages taken. Sample total bacterial copy number was calculated per µL of 
DNA eluate against a standard curve of a known bacterial copy number.  
 
Sequence data processing 
The Quantitative Insights Into Microbial Ecology (QIIME, v1.8.0)9 software was used to 
analyse the 16S rRNA sequence generated from paired-end amplicon sequencing using 
bioinformatics pipeline as previously described.10 Briefly, barcoded forward and reverse 
sequencing reads were quality filtered and merged using Paired-End reAd mergeR (PEAR 
v0.9.6).11 Chimeras were detected and filtered from the paired-end reads using USEARCH 
(v6.1)12 against the 97% clustered representative sequences from the Greengenes database 
(v13.8).13 Operational taxonomic units (OTUs) were assigned to the reads using an open 
reference approach with UCLUST algorithm (v1.2.22q) against the SILVA database release 
111 (July 2012)14 that was clustered at 97% identity. Spurious OTUs were then removed 
systematically using previous reports of common laboratory sequencing contaminants.15 A 
minimum subsampling depth of 1,732 reads was then selected for all samples.  
Where taxa assignment failed to classify to the Family or Genus level, OTU reference 
sequences (accounting for >99% of OTU reads) were separately aligned using SILVA 
Incremental Aligner (SINA) (https://www.arb-silva.de/) which uses SILVA, RDP, 
Greengenes, LTP and EMBL sequence collections. If the alignments identified taxa to a 
genus level, and at >99% similarity, they replaced the previous taxon assignment. This 
occurred for Streptococcus II which was previously incorrectly assigned as 
Clostridiales;Other;Other. Streptococcus I refers to the OTU cluster which was assigned as 
Streptococcus during initial assignment.  
 
Diversity measurements and statistical analyses 
Bray-Curtis matrix was calculated based on sample-normalised, square root transformed 
relative taxon abundance. Principal coordinate analysis (PCoA) was used to visualize 
clustering of samples based on their similarity matrices with PCO1 and PCO2 coordinates and 
group centroids plotted using ggplot2 package of R statistical software.16 Distance from 
centroid was calculated as previously described, using PRIMER.17 Permutational multivariate 
analysis of variance (PERMANOVA)18 on the beta-diversity matrices was used to test the 
null hypothesis of no difference amongst a priori-defined groups using PERMANOVA + add-
on package for PRIMER. The test was computed using unrestricted permutation of raw data 
with 9,999 random permutations and at a significance level of 0.01. 
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Taxon dispersion  
Variation in microbiota composition at the genus-level was assessed using multiple 
approaches. First, taxa that contributed to the overall variation between the asthma 
phenotypes were identified using SIMilarity of PERcentages (SIMPER) analysis in PRIMER. 
Subsequently, the abundance of the 13 highest ranked taxa (accounting for 50% of the 
dissimilarity between neutrophilic and eosinophilic groups) were used to generate a heatmap 
using ggplot2 package of R statistical software.16 Hierarchical clustering of the taxa was 
performed on Bray-Curtis dissimilarity and clustered using single linkage method. 
Dominance of Haemophilus and Moraxella was determined when the relative abundance of 
each taxa exceeded 40%. This cut-off was selected based to the distribution of the relative 
abundance, where a clear distinction between samples with >40% and <40% was evident, 
suggesting overgrowth of these taxa.  
Second, strong taxon-taxon correlations were identified using SparCC,19 where absolute taxon 
abundances were bootstrapped 100 times to generate correlation p values. Networks were 
then generated from selected correlations (r≥0.25 or r≤-0.25) and p values (p≤0.01) using 
Cytoscape (version 3.4.0).  
Two approaches were used to investigate the impact of pathogen overgrowth on microbiota 
composition. First, in samples where Haemophilus or Moraxella were the dominant taxon and 
represented > 40% of total reads, their relative abundance was adjusted to the mean value for 
the study cohort and the remaining relative abundance measures rescaled, as described 
previously.20 PERMANOVA analyses were then performed on the rescaled data. Second, 
pairwise comparisons between neutrophilic and eosinophilic samples were performed using 
the phyloseq R package21 with DEseq222 extension, based on count data. p values were 
corrected using the Benjamini-Hochberg false discovery rate procedure and a corrected alpha 
value cut-off of <0.05 used for inclusion. 
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Supplementary Figure 1: Bacterial burden as assessed by 16S rRNA gene copy number. 
Bars show the median±95% CI. Statistical significance was assessed by Kruskal-Wallis one-
way ANOVA with Dunn’s post hoc test. No significant difference between phenotypes. 
Supplementary Figure 2. Alpha diversity measures among asthma phenotypes. A) Taxa 
richness, B) Shannon-Wiener index, C) Simpson’s evenness index, D) Pielou’s evenness. 
Bars show the median±95% CI. Statistical significance was assessed by Kruskal-Wallis one-
way ANOVA with Dunn’s post hoc test.  
Supplementary Figure 3: Correlations between sputum neutrophil/eosinophil counts (as a 
percentage of total cell count) and alpha diversity measures. A) Neutrophil % where dotted 
line at 61% neutrophils indicates phenotype cut-off point. B) Eosinophil % where dotted line 
at 3% eosinophils indicates phenotype cut-off point. Colours represent asthma phenotype, 
based on neutrophilia or eosinophilia where blue= >61% neutrophils, green= >3% 
eosinophils, yellow= <61% neutrophils and <3% eosinophils (paucigranulocytic), and  
purple= both >61% neutrophils and >3% eosinophils (mixed). Statistical significance was 
assessed by Spearman’s rank correlation. 
Supplementary Figure 4: Correlations between sputum neutrophil/eosinophil counts (as a 
percentage of total cell count) and weighted UniFrac distance from centroid. A) Neutrophil % 
where dotted line at 61% neutrophils indicates phenotype cut-off point. B) Eosinophil % 
where dotted line at 3% eosinophils indicates phenotype cut-off point. Colours represent 
asthma phenotype, based on neutrophilia or eosinophilia where blue= >61% neutrophils, 
green= >3% eosinophils, yellow= <61% neutrophils and <3% eosinophils 
(paucigranulocytic), and purple= both >61% neutrophils and >3% eosinophils (mixed). 
Statistical significance was assessed by Spearman’s rank correlation. 
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Supplementary Figure 5: A) Principal Coordinate Analysis (PCoA) of asthma phenotype 
groups based on Bray-Curtis similarity distances. The first two principal coordinates are 
plotted on the x- and y-axes, respectively (representing 36.5% of the total variation). B) 
Microbiota dispersion grouped by asthma phenotype. Distance from centroid calculated from 
Bray-Curtis dissimilarity matrix. C,D) Correlations between sputum inflammatory cell 
percentages and distance from centroid. C) Sputum neutrophil % vs Bray-Curtis distance 
from centroid. D) Sputum eosinophil % vs Bray-Curtis distance from centroid. 
Supplementary Figure 6: Figure legend for bacterial network analysis. Showing weight and 
colour assigned to edges and nodes. 
Supplementary Figure 7: Taxa which significantly correlated with eosinophil %. Colours 
represent asthma phenotype, based on neutrophilia or eosinophilia where blue= >61% 
neutrophils, green= >3% eosinophils, yellow= <61% neutrophils and <3% eosinophils 
(paucigranulocytic), and purple= both >61% neutrophils and >3% eosinophils (mixed). 
Dotted line at 3% eosinophils indicate phenotype cut-off points. Statistical significance was 
assessed by Spearman’s rank correlation. 
Supplementary Figure 8: Normalised, log2 fold changes of non-rarefied taxa read counts 
which significantly (p<0.05) differed between neutrophilic and eosinophilic phenotypes. 
Positive fold change indicates taxon which were significantly higher counts in neutrophilic 
participants, negative fold change indicates taxon which were significantly higher in 
eosinophilic participants. Showing that, when Haemophilus or Moraxella dominance do not 
influence data (due to non-rarefied count data as opposed to relative abundance), multiple 
taxa remain significantly different between neutrophilic and eosinophilic participants.  
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Supplementary Table 1: 16S rRNA sequencing information 
Median read count (Q1, Q3) 12792 (8060, 16595) 
Subsample depth 1732 
Samples excluded 7 
Median Good’s coverage (Q1, 
Q3) 
0.952 (0.942, 0.963) 
 
 
Supplementary Table 2: PERMANOVA analysis testing significance of variance of 
Weighted UniFrac and Bray-Curtis Distance of sputum microbiota between asthma 
phenotypes (permutations = 9999) 
Matrix Source Df SS MS Pseudo-F P(perm) 
Weighted 
UniFrac 
Phenotype 3 9444.4 3148.1 3.9969 0.0004 
Residual 163 128390 787.64   
Total 166 137830          
Bray-
Curtis 
Phenotype 3 8215.4 2738.5 3.3694 0.0001 
Residual 163 132480 812.74   
Total 166 140690          
 
 
Supplementary Table 3: Pairwise PERMANOVA analysis testing significance of 
variance of Weighted UniFrac and Bray-Curtis Distance of sputum microbiota between 
asthma phenotypes (permutations = 9999) 
Matrix Groups T P(perm) Unique perms 
Weighted 
UniFrac 
Pauci vs Neutro 2.52 <0.01 9943 
Pauci vs Eosino 1.28 0.13 9928 
Pauci vs Mixed 0.80 0.62 9952 
Neutro vs Eosino 3.30 <0.0001 9924 
Neutro vs Mixed 1.20 0.21 9876 
Eosino vs Mixed 1.19 0.19 9939 
Bray-
Curtis 
Neutro vs Eosino 2.89 <0.0001 9928 
Neutro vs Pauci 2.43 <0.001 9918 
Neutro vs Mixed 1.18 0.19 9888 
Eosino vs Pauci 1.15 0.17 9921 
Eosino vs Mixed 0.96 0.50 9899 
Pauci vs Mixed 0.78 0.83 9922 
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Supplementary Table 4: Similarity of percentages (SIMPER) analysis comparing taxa 
relative abundances between neutrophilic and eosinophilic phenotype groups. Showing 
thirteen top contributing taxa which collectively account for approximately 50% of 
variance between groups.  
 
 
Supplementary Table 5: Top: PERMANOVA analysis, Bottom: Pairwise 
PERMANOVA on non-dominant microbiome. Bray-Curtis Distance of sputum 
microbiota on the genera level, grouped by asthma phenotype (permutations = 9999). 
Source Df SS MS Pseudo-F P(perm) 
Phenotype 3 5381 1793.7 2.378 0.0004 
Residual 163 122950 754.3   
Total 166 128330          
Groups T P(perm) Unique perms 
Neutro vs Eosino 2.31 <0.0001 9922 
Neutro vs Pauci 2.26 <0.001 9911 
Neutro vs Mixed 1.11 0.24 9857 
Eosino vs Pauci 0.91 0.65 9904 
Eosino vs Mixed 0.79 0.86 9921 
Pauci vs Mixed 0.73 0.92 9924 
 
 
Neutrophili
c 
Eosinophili
c                  
Species Av. Abund Av. Abund Av. Diss Contrib % 
Haemophilus 0.41 0.2 4.49 8.89 
Prevotella 0.23 0.33 2.61 5.16 
Streptococcus II 0.13 0.27 2.58 5.11 
Streptococcus I 0.45 0.51 2.34 4.63 
Veillonella 0.2 0.22 1.98 3.91 
Moraxella 0.13 0 1.88 3.72 
Neisseria 0.11 0.19 1.65 3.26 
Rothia 0.1 0.19 1.52 3 
Actinomyces sp. uncultured 
bacterium 0.1 0.16 1.5 2.96 
Gemella 0.09 0.17 1.26 2.49 
Leptotrichia 0.08 0.11 1.2 2.38 
Actinomyces sp. oral clone DR002 0.05 0.08 1.1 2.17 
Porphyromonas 0.04 0.11 1.1 2.17 
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